Quantum Biopharma Ltd. QNTM
3.85
(0.15)
(3.75%)
as of 25 Sep
- Market cap
- $30.9M
- P/E
- 0.0×
Follow QNTM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (618.06%) | (2,004.30%) | (336.82%) | (247.86%) |
+8 more TTM periods Free account |
|
| (169.48%) | (209.12%) | (185.11%) | (170.71%) | ||
ROIC |
0.00% | 0.00% | (1,823.09%) | (984.74%) | |
Return on Tangible Assets |
(1,457.97%) | 527.01% | (5,373.70%) | (1,023.82%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.34) | (2.04) | (3.46) | (3.37) | |
Free Cash Flow |
(8.94) | (9.14) | (11.37) | (12.79) | |
Capital Expenditures |
(3.46) | (3.49) | (3.13) | (4.03) | |
| Other line items | |||||
Cash ROIC |
(34.63%) | (65.54%) | (85.09%) | (63.55%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.22 | 0.18 | 0.31 | 0.31 | |
Depreciation/Fixed assets |
8.57 | 8.43 | 8.15 | 7.61 | |
Capex/Depreciation |
(6.52) | (6.43) | (5.74) | (7.61) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.82) | (1.26) | (2.51) | (2.31) | |
Capex per Share |
(0.52) | (0.78) | (0.95) | (1.06) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates